Semaglutide treatment for children with obesity: an observational study.
Arch Dis Child
; 109(10): 822-825, 2024 Sep 25.
Article
em En
| MEDLINE
| ID: mdl-38471743
ABSTRACT
OBJECTIVE:
To assess efficacy and tolerability of semaglutide as a weight loss treatment for children living with comorbid obesity.DESIGN:
Retrospective observational study of the first 50 children from a weight management service treated with semaglutide for at least 6 months.SETTING:
A tertiary paediatric multidisciplinary weight management clinic in a UK hospital. PATIENTS Aged 10-18 years old with a body mass index (BMI) SD score (SDS) >2 with a weight-related comorbidity (including insulin resistance (defined as homeostatic model assessment for insulin resistance >4), type 2 diabetes, metabolic-associated fatty liver disease, obstructive sleep apnoea or hypertension).INTERVENTIONS:
Once-weekly injectable semaglutide titrated over 8 weeks to a final dose of 1 mg in addition to dietary and lifestyle advice. MAIN OUTCOMEMEASURES:
Primary outcome measures were change in weight, BMI SDS and percentage body weight. Secondary outcomes were side effects and cessation of treatment.RESULTS:
After 6 months of treatment, statistically significant decreases in BMI SDS (0.32±0.27, p<0.001) and body weight (7.03±7.50 kg, p<0.001) were seen. Mean percentage total weight loss was 6.4±6.3% (p<0.001). For the 14 patients for whom 12-month data were available, statistically significant decreases were seen in mean BMI SDS (0.54±0.52, p<0.001). Mean body weight decreased by 9.7±10.8 kg (p<0.001). Percentage total weight loss at 12 months was 8.9±10.0% (p<0.001). Mild gastrointestinal side effects were common. One patient developed gallstones. Five patients discontinued treatment due to side effects.CONCLUSION:
Semaglutide appears to be a safe and effective weight loss adjunct when used in a multidisciplinary weight management clinic.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Redução de Peso
/
Índice de Massa Corporal
/
Peptídeos Semelhantes ao Glucagon
/
Obesidade Infantil
Limite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Arch Dis Child
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Reino Unido